...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >DESIGN AND OPTIMIZATION OF CONTROLLED RELEASE OCULAR INSERTS OF DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE FOR TREATMENT OF GLAUCOMA
【24h】

DESIGN AND OPTIMIZATION OF CONTROLLED RELEASE OCULAR INSERTS OF DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE FOR TREATMENT OF GLAUCOMA

机译:治疗青光眼的可控释氢吡咯酰胺和马来酸替莫洛尔的控释耳蜗设计与优化

获取原文
           

摘要

Goal of the present investigation was to formulate ocular inserts of dorzolamide hydrochloride and timolol maleate for the treatment of glaucoma. Ocular inserts of dorzolamide hydrochloride and timolol maleate were prepared using different polymers ethylcellulose, Eudragit RL 100, and Eudragit RS100 by solvent casting method with an objective to increasing the contact time, achieving controlled release, reducing in frequency of administration, and improving therapeutic efficacy. The drug-excipients interaction was studied by Fourier transform infrared spectroscopy (FTIR) studies. Prepared ocular inserts were evaluated for their physicochemical properties such as uniformity of thickness, weight uniformity, tensile strength, percentage elongation, drug content, moisture loss, moisture absorption. The in vitro diffusion of drug from the inserts was studied using the classical biochemical donor – receptor compartment model fabricated in the laboratory and the formulation that showed better release profile was subjected to in vivo studies on albino-rabbits. Ocular irritation study was performed using healthy albino rabbits and confirmed that there was no irritation in the rabbit eyes. All the inserts were found to be uniform thickness and uniform weight. The inserts possessed good tensile strength and percentage elongation. All the formulations followed a first order release pattern. Optimized formulation RSRL3 showed high correlation coefficient (R = 0.996 & 0.995 respectively for dorzolamide HCl & timolol maleate) between in vitro and in vivo release. Stability study was carried out on RSRL3 formulation and showed no significant changes in the drug content as well as physical characteristics of the film.
机译:本研究的目的是配制盐酸多佐酰胺和马来酸替莫洛尔的眼用制剂,以治疗青光眼。通过溶剂流延法,使用不同的聚合物乙基纤维素,Eudragit RL 100和Eudragit RS100制备盐酸多佐胺盐酸盐和马来酸替莫洛尔的眼用插入剂,目的是增加接触时间,实现控释,减少给药频率并提高治疗效果。通过傅立叶变换红外光谱(FTIR)研究来研究药物与辅料的相互作用。评估所制备的眼用插入物的理化性质,例如厚度均匀性,重量均匀性,拉伸强度,伸长率百分比,药物含量,水分损失,水分吸收。使用实验室中制造的经典生化供体-受体区室模型研究了药物从插入物中的体外扩散,并对显示出更好释放曲线的制剂进行了白化兔体内研究。对健康的白化病兔子进行了眼刺激研究,并确认兔子的眼睛没有刺激。发现所有插件的厚度和重量均一。刀片具有良好的拉伸强度和伸长率。所有制剂均遵循一阶释放模式。优化的配方RSRL3在体内和体外释放之间显示出很高的相关系数(盐酸多佐酰胺和马来酸替莫洛尔分别为R = 0.996和0.995)。对RSRL3制剂进行了稳定性研究,结果表明药物含量以及薄膜的物理特性没有明显变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号